Erfan Bashar
Back to Cardiomyopathies

Fabry Disease

~3 min read
Last medically reviewed:
On this pageTable of contents

Educational scope notice: This is a study note for medical students, not medical advice, diagnosis, or treatment guidance. Clinical management should follow local protocols and current guidelines.

Fabry disease is an X-linked lysosomal storage disorder. Mutations in the GLA gene cripple alpha-galactosidase, the enzyme that degrades glycosphingolipids — lipid components present in every cell — so these lipids accumulate inside cellular organelles. The disease is systemic, but cardiac involvement drives prognosis.

Inheritance and timing

The GLA gene sits on the X chromosome. Males with the affected X chromosome have a very high probability of expressing disease, while females, with a second X chromosome that may compensate, show a wide range from silent to mild forms that ECG and echocardiography can miss. Not all mutations behave alike: classic mutations with severe enzyme dysfunction declare themselves from the second to fourth decade, whereas late-onset mutations with milder impairment accumulate slowly and may surface as late as the eighth decade.

What storage does to the heart

Lipid engorgement inside myocardial cells makes the actin–myosin interaction ineffective, so macroscopic systolic thickening falls. Over years affected cells die and scar replaces them. The result is progressive systolic dysfunction — the main haemodynamic burden, unlike the restrictive course of amyloidosis — affecting both ventricles, with fibrotic scar supplying the substrate for ventricular arrhythmias, syncope, and sudden death. In end-stage disease the weakened muscle cannot generate adequate stroke volume. The teaching follow-up case places the course from first severe systolic dysfunction to death at roughly 2–3 years in untreated late-onset disease.

The imaging signature

Tissue imaging, explained in the cardiac MRI note, gives the characteristic combination:

  • Native T1 lowered diffusely across all segments, reflecting intracellular lipid storage. A diffusely low T1 is unusual and narrows the differential sharply.
  • Oedema signal minimal — the process is chronic rather than inflammatory, with at most small scattered areas.
  • Enhancement midmyocardial and segmental: a pale band sandwiched between darker inner and outer layers, a typical non-ischaemic distribution.
  • Extracellular volume raised only where scar sits. Unaffected areas read normal, around 24–28%, because Fabry is primarily an intracellular disease — the extracellular space expands only where dead cells have been replaced by fibrosis.

The mirror image helps memory: cardiac amyloidosis raises T1 and ECV diffusely in every segment, while Fabry lowers T1 diffusely and raises ECV only in scarred segments.

Why diagnosis comes late, and why early matters

The teaching case is sobering: years of unexplained ECG changes, a moderate coronary stenosis insufficient to explain them, progressive atrial fibrillation, and eventual severe biventricular failure — with Fabry unrecognised throughout. Imaging at the first unexplained ECG change would have shown the characteristic low T1 and prompted genetic testing while function was still normal. Early diagnosis matters for two reasons. Disease-modifying treatment can slow or halt progression before irreversible fibrosis, and every proband implies a family: relatives may carry the same mutation, including women with subclinical disease.

Treatment principles

The teaching sources cover mechanisms without drug names or dosing, and this note respects that boundary. Enzyme replacement therapy, available since approximately 2001 with at least two initial products and now a third, supplies functional alpha-galactosidase to clear stored lipid. Chaperone therapy works differently: it stabilises the patient’s own misfolded enzyme so it functions more effectively. Drug names, dosing, pharmacokinetics, and comparative efficacy belong to guidelines and formularies.

Screening the family

Once a proband is diagnosed, at-risk relatives merit screening. Male relatives carrying the mutation are likely already expressing disease. Female relatives need particular attention: X-inactivation chance decides severity, so a normal ECG and echocardiogram do not exclude carriage — genetic testing and tissue imaging reveal subclinical disease.

A continuum, not a switch

Fabry tissue injury progresses in stages rather than flipping overnight. Falling T1 appears first, reflecting silent storage with normal oedema imaging and no scar. Oedema follows in some cells, then cell death with enhancement, then progressive fibrosis and systolic decline — and early oedema spatially matches where scar later appears. Treatment started before scar develops may still reverse the process; established fibrosis is irreversible.

Evidence anchors

Suggest a correction